Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 24, 2017

Primary Completion Date

August 20, 2019

Study Completion Date

November 28, 2019

Conditions

Mesenchymal Stromal CellsPsoriasisDrug ToxicityDrug Effect

Interventions

BIOLOGICAL

adipose-derived multipotent mesenchymal stem cells

AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 0.5 million cells/kg.

Trial Locations (1)

Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou

All Listed Sponsors

lead

Guangdong Provincial Hospital of Traditional Chinese Medicine

OTHER

NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis | Biotech Hunter | Biotech Hunter